Feasibility Study Comparing Use of One Or Two Probes for Thermal Ablation Among Cervical Cancer S⦠(NCT07468695) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Feasibility Study Comparing Use of One Or Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive Women Living With HIV in C1001P-CS2 Kenya
Kenya300 participantsStarted 2026-03
Plain-language summary
Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general population. Thermal ablation (TA) is recommended by the World Health Organization (WHO) to treat cervical precancerous lesions, although its efficacy can be suboptimal in WLWH. In Kenya, the estimated incidence rate of cervical cancer is 31-33 per 100,000 women per year among women without HIV and approximately 70-100 per 100,000 among WLWH.
The proposed study will evaluate the feasibility, acceptability, and safety of a two-probe TA technique (endocervical and ectocervical probes) and whether this approach improves treatment outcomes among WLWH compared to one (ectocervical) probe. This innovation has the potential to significantly enhance cervical cancer prevention efforts in high-burden settings. It will also contribute towards achieving the 90-70-90 goals of the WHO strategy for accelerated elimination of cervical cancer as a public health problem by 2030.
Who can participate
Age range25 Years ā 49 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. 25-49 years old
ā. Living with HIV
ā. Intact cervix
ā. Willing to return to facility at 6 months
ā. Willing and able to provide informed consent
ā. Positive hrHPV or VIA test within 3 months of enrollment
ā. Type 1 transformation zone (TZ1)
ā. Thermal ablation eligible
Exclusion criteria
ā. Screened for cervical cancer outside of study in last 6 months
ā. Currently pregnant or less than 6 weeks postpartum
ā. Prior diagnosis of cervical cancer
ā. A history of treatment for cervical precancer
What they're measuring
1
Proportion of participants with persistent HPV at 6 months
Timeframe: From enrollment to follow up at 6 months
ā. Individual has a condition that the Clinical Site PI believes will interfere with or affect the conduct, results, or completion of the clinical study
ā. Individual has a condition that the Clinical Site PI considers creates an unacceptable risk to the individual if enrolled